SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Amneal Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

03168L105

(CUSIP Numbers)

Christine Krentz
4 Gatehall Drive,
Parsippany, NJ, 07054
(908) 409-6700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/10/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D/A

CUSIP Number(s):	03168L105

1	**Name of reporting person** Chintu Patel
2	**Check the appropriate box if a member of a Group (See Instructions)** ☒ (a) ☐ (b)
3	**SEC use only**
4	**Source of funds (See Instructions)** OO
5	**Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)** ☐
6	**Citizenship or place of organization** UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 **Sole Voting Power:** 32,576,528.00 8 **Shared Voting Power:** 0.00 9 **Sole Dispositive Power:** 32,576,528.00 10 **Shared Dispositive Power:** 0.00
11	**Aggregate amount beneficially owned by each reporting person** 32,576,528.00
12	**Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)** ☐
13	**Percent of class represented by amount in Row (11)** 9.4 %
14	**Type of Reporting Person (See Instructions)** IN

Comment for Type of Reporting Person: The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition (as defined below), as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026.

SCHEDULE 13D/A

Item 1. Security and Issuer

(a) Title of Class of Securities:

Class A Common Stock, par value $0.01

(b) Name of Issuer:

Amneal Pharmaceuticals, Inc.

(c) Address of Issuer's Principal Executive Offices:

400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER, NEW JERSEY , 08807.

Item 3. Source and Amount of Funds or Other Consideration

The disclosure in Item 3 is hereby amended and supplemented by adding the following:

On April 21, 2026, CKR Dynasty, LLC, a Delaware limited liability company ("CKR") the sole manager of which is the Reporting Person, and Shivkan Holdings, LLC, a Delaware limited liability company ("Shivkan") the sole members of which are trusts controlled by the Reporting Person, entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC (the "Seller Representative") and the equityholders of Kashiv named therein, including CKR and Shivkan (the "Sellers"). On August 10, 2026, pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Amneal LLC"), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller Representative, purchased from the Sellers, including CKR and Shivkan, and the Sellers, including CKR and Shivkan sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the "Kashiv Acquisition"). Pursuant to the Purchase Agreement, at the closing of the Kashiv Acquisition, (i) Amneal LLC was required to pay to the Sellers, including CKR and Shivkan, an aggregate amount of $375,000,000 in cash, subject to certain purchase price adjustments, and (ii) Amneal was required to issue to the Sellers, including CKR and Shivkan, an aggregate of 28,942,098 shares of Class A Common Stock. CKR was issued 2,807,963 shares of Class A Common Stock, and Shivkan was issued 3,573,771 shares of Class A Common Stock, in connection with the Kashiv Acquisition.

Item 4. Purpose of Transaction

This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition, as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026:

(b) Reporting Person - Chintu Patel
Amount beneficially owned - 32,576,528
Percent of class - 9.4
Sole power to vote or to direct the vote - 32,576,528
Shared power to vote or to direct the vote - 0
Sole power to dispose or to direct the disposition - 32,576,528
Shared power to dispose or to direct the disposition - 0

The Reporting Person owns directly (i) 1,388,521 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028 and (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and may be deemed to beneficially own 11,495,965 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person, 13,257,287 shares of Class A Common Stock held of record by Shivkan Holdings X, LLC, a Delaware limited liability company, 3,573,771 shares of Class A Common Stock held of record by Shivkan, and 2,807,963 shares of Class A Common Stock held by CKR.

(c) The information set forth in Item 3 of this Amendment No. 5 is incorporated by reference herein

(d) None.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chintu Patel

Signature:	**/s/ Chintu Patel**
Name/Title:	**Chintu Patel**
Date:	**08/12/2026**